By Michelle Gardner
Duringthe past, indiscriminate use of antibiotics has given once-susceptible bacteriathe chance to develop defenses against antibiotics, thus providing theopportunity for resistant strains to flourish. Reports of vancomycin-resistant enterococcus(VRE) and methicillin-resistant Staphylococcus aureus (MRSA) haveincreased in oncology units of large teaching hospitals, and nursing homes,long-term care facilities, and community hospitals, respectively.
Both Enterococci and Staphylococcus are part of the body'snormal flora, which is considered "good" bacteria and essential forhuman health.4 But if the body's natural defense system breaks down (i.e.,after an invasive procedure, trauma, or chemotherapy), these normally benignbacteria can invade tissue, proliferate, and cause infection.
At one time, enterococcal infections were easily treated with high doses ofpenicillin or ampicillin, which progressed to aminoglycosides, then vancomycin.Many clinicians suspect that over reliance on vancomycin led to the developmentof VRE, which isn't easily treated with any antibiotic.
Who's at risk?
Patients most at risk for VRE include, but are not limited to,immunosuppressed patients or those with severe underlying disease; elderlypatients, especially those who've had prolonged or repeated hospital admissions;patients with wounds with an opening to the pelvic or intra-abdominal area,including surgical wounds, burns, and pressure ulcers; and patients exposed tocontaminated equipment or to a VRE-positive patient.
According to the Centers for Disease Control and Prevention (CDC), infectedpatients carry VRE and show clinical signs or symptoms of disease. Colonizedpatients carry VRE but do not have clinical signs or symptoms of infection.Patients are usually colonized in the gastrointestinal tract and occasionally inthe urinary tract. The goal of screening is to identify as many colonizedpatients as possible so that infection control measures can be implemented todecrease transmission and reduce the number of patients infected with VRE.
VRE is spread through direct contact between patient and caregiver, orpatient to patient. It also can be spread through patient contact withcontaminated surfaces. VRE has been detected on patient gowns, bed linens, andhandrails.
Understanding MRSA
Patients most at risk for MRSA include immunosuppressed patients, burnpatients, intubated patients, and those with central venous catheters, surgicalwounds, or dermatitis.
Risk factors include prolonged hospital stays, extended therapy with multipleor broad-spectrum antibiotics, and close proximity to those colonized orinfected with MRSA.
Like VRE, MRSA enters health care facilities through an infected or colonizedpatient or colonized healthcare worker (HCW). Although MRSA has been recoveredfrom environmental surfaces, it's transmitted mainly on HCWs' hands. Typically,MRSA colonization is diagnosed by isolating bacteria from nasal secretions as40% of adults and most children become transient nasal carriers.
The following guidelines apply when caring for a patient with MRSA or VRE:
More bad bugs
Besides MRSA and VRE, antibiotic-resistant organisms continue to appear:
S. aureus intermediately resistant to vancomycin (known by the acronymVISA). To prevent the rise of VRSA and other antibiotic-resistant organisms, usesimilar techniques for preventing the spread of VRE and MRSA. Among the mostimportant measures: good hand washing, barrier precautions, and continuedvigilance against the spread of these organisms.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.